



Disclosures

Personal Commercial (43)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|--------------------------|---|
| <i>Self</i> | | | |
| Abbott | Research/Research Grants ‡ COAPT, EXCEL, ILUMIEN IV, ABSORB IV | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Abiomed | Research/Research Grants ‡ PROTECT IV, RECOVER IV | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Abiomed | Consultant Fees/Honoraria | Modest (< \$5,000) | Invasive CV Angio and Interventions |
| Ablative Solutions | Consultant Fees/Honoraria | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Adona Medical | Consultant Fees/Honoraria | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Ancora | Stock | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Ancora | Consultant Fees/Honoraria | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Apollo Therapeutics | Consultant Fees/Honoraria | Significant (>= \$5,000) | Acute Coronary Syndromes |
| Applied Therapeutics | Stock | Significant (>= \$5,000) | General Cardiology |
| Aria | Stock | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Biosense Webster | Research/Research Grants ‡ Wavecrest II | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Biostar family funds | Stock | Significant (>= \$5,000) | Invasive CV Angio and Interventions General Cardiology |
| Bioventrix | Research/Research Grants ‡ ALIVE trial | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Boehringer Ingelheim Pharmaceuticals, Inc | Consultant Fees/Honoraria | Modest (< \$5,000) | General Cardiology |
| Cagent | Stock | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Cardiac Success | Consultant Fees/Honoraria | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Cardiac Success | Stock | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Cardiovascular Systems Inc. | Research/Research Grants ‡ ECLIPSE | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Daiichi Sankyo | Consultant Fees/Honoraria | Modest (< \$5,000) | Acute Coronary Syndromes |
| Elixir | Consultant Fees/Honoraria | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Elucid Bioimaging | Consultant Fees/Honoraria | Significant (>= \$5,000) | General Cardiology |
| HeartFlow | Consultant Fees/Honoraria | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| HighLife | Consultant Fees/Honoraria | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Impulse Dynamics | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Millennia Biopharma | Consultant Fees/Honoraria | Significant (>= \$5,000) | General Cardiology |
| Miracor | Consultant Fees/Honoraria | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Neovasc | Consultant Fees/Honoraria | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Occlutech | Consultant Fees/Honoraria | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Orchestra Biomed | Stock | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Oxotope | Consultant Fees/Honoraria | Significant (>= \$5,000) | Acute Coronary Syndromes |
| Phillips | Research/Research Grants ‡ DEFINE-GPS | None (\$0) | Invasive CV Angio and Interventions |

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|--|--|--------------------------|-------------------------------------|
| Pulnovo | Research/Research Grants ‡ PADN-PLANR | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Robocath | Consultant Fees/Honoraria | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Shockwave | Research/Research Grants ‡ DISRUPT CAD III | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Spectrawave | Stock | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| TherOx | Consultant Fees/Honoraria | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Valfix | Stock | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Valfix | Consultant Fees/Honoraria | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Vascular Dynamics | Other - Institutional research grant for future trials | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Vectorious | Consultant Fees/Honoraria | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| V-wave | Research/Research Grants ‡ RELIEVE-HF | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Xenter | Stock | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Spouse/Domestic Partner/Immediate Household Member | | | |
| IQVIA | Other - My daughter is an employee at IQVIA | Significant (>= \$5,000) | Invasive CV Angio and Interventions |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/12/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/12/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/12/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/12/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.